Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Antitumor effects of CEP32496 on urothelial carcinoma with BRAF mutation (V595E) in dogs.

Canadian journal of veterinary research = Revue canadienne de recherche veterinaire - 1 Oct 2026

Yamasaki Hirofumi, Hiramatsu Hiromi, Nakamichi Jun, Tei Meina, Uematsu Yosuke, Uchida Kazuyuki, Ono Kenichiro, Hirao Hidehiro

Abstract excerpt

Canine urothelial carcinoma (UC) has a BRAF gene mutation (V595E) with a high prevalence rate (67 to 87%). CEP32496 is a novel and highly potent BRAF inhibitor. As described in the literature, the efficacy of BRAF inhibitors, including CEP32496, for UC with V595E is limited. The objective of this study was to evaluate the effects of CEP32496 alone and in combination with other BRAF inhibitors on the cell...

Read the complete abstract on PubMed

Topics

Animals
Dogs
Proto-Oncogene Proteins B-raf
Dog Diseases
Antineoplastic Agents
Cell Line, Tumor

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Mutation

Sulfonamides

Urinary Bladder Neoplasms

Indoles

Pyrroles

Source

Open in PubMed Open full text

Identifiers

PMID: 42775191
PMCID: PMC13595404

Genes

BRAF

Variants

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 23 Oct 2026.

Related research

Semantic proximity does not establish scientific evidence. Graph snapshot: 2026-09-29.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Antitumor effects of CEP32496 on urothelial carcinoma with BRAF mutation (V595E) in dogs.PMID 42775191Read ↗

Establishment of Canine Transitional Cell Carcinoma Cell Lines Harboring BRAF V595E Mutation as a Therapeutic Target.Semantic proximity Read ↗

Phase I/II Trial of Vemurafenib in Dogs with Naturally Occurring, BRAF-mutated Urothelial Carcinoma.Semantic proximity Read ↗

Establishment and characterization of urothelial carcinoma cell lines with and without BRAF mutation (V595E) in dogs.Semantic proximity Read ↗

BRAF mutation status and its prognostic significance in 79 canine urothelial carcinomas: A retrospective study (2006-2019).Semantic proximity Read ↗

Identifying the ErbB/MAPK Signaling Cascade as a Therapeutic Target in Canine Bladder Cancer.Semantic proximity Read ↗

Effective detection of BRAFV595E mutation in canine urothelial and prostate carcinomas using immunohistochemistry.Semantic proximity Read ↗

Homologous Mutation to Human BRAF V600E Is Common in Naturally Occurring Canine Bladder Cancer--Evidence for a Relevant Model System and Urine-Based Diagnostic Test.Semantic proximity Read ↗

BRAF Mutations in Canine Cancers.Semantic proximity Read ↗

Proteomic Signatures of Vemurafenib Resistance in Canine Urothelial Carcinoma Harboring the BRAFV595E Mutation.Semantic proximity Read ↗

Establishment of a BRAF V595E-mutant canine prostate cancer cell line and the antitumor effects of MEK inhibitors against canine prostate cancer.Semantic proximity Read ↗

Management of transitional cell carcinoma of the urinary bladder in dogs: a review.Semantic proximity Read ↗

BRAF Mutation Analysis: A Retrospective Evaluation of 8365 Diagnostic Samples with a Special View on Canine Breeds (2018–2024)Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.